Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity

BJU International

Volumn 100, Issue 6, 2007, Pages 1302-1306

  Jeffery, Stephen ^a   Fynes, Michelle ^a   Lee, Frank ^a   Wang, Kate ^a   Williams, Lin ^b   Morley, Roland ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b KINGSTON HOSPITAL   (United Kingdom)

Author keywords

Botulinum toxin A; Dysport; Idiopathic detrusor overactivity; Overactive bladder

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CATHETERIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DETRUSOR DYSSYNERGIA; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; INCONTINENCE; MALE; MICTURITION; MUSCLE WEAKNESS; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; SYMPTOM; URINARY TRACT INFECTION; URODYNAMICS; UROFLOWMETRY; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS;

EID: 35748983517     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07186.x     Document Type: Article

References (23)

1. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 14
2. Reeves P, Irwin D, Kelleher C et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006 50 : 1050 7
3. McKillop C. Interview with Chris Chapple. Overactive Bladder: tackling the problem. Eur Urol 2006 49 : 921 3
4. Flood HD, Malhorta SJ, Connel HC et al. Long term results and complications using augmentation cystoplasty and reconstruction urology. Neurourol Urodyn 1995 14 : 297 309
5. Kalsi V, Popat RB, Apostolidis A et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006 49 : 519 27
6. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 2006 50 : 684 709
7. Schurch B, Stöhrer M, Kramer D, Schmid M, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2005 174 : 196 200
8. Reitz A, Stöhrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004 45 : 510 5
9. Popat R, Apostolides A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005 174 : 984 9
10. Odergren T, Hjaltason H, Kaakkala S et al. A double-blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998 64 : 6 12
11. Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A Toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005 47 : 653 9
12. Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006 97 : 1030 4
13. Patki PS, Hamid R, Arumugam K, Shah PJ, Craggs M. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 2006 98 : 77 82
14. Bidmead J, Cardozo L, McLellan A, Khullar V, Kelleher C. A comparison of the objective and subjective outcomes of colposuspension for stress incontinence in women. BJOG 2001 108 : 408 13
15. Schurch B, de Seze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomised, placebo controlled 6-month study. J Urol 2005 174 : 196 200
16. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005 192 : 1735 40
17. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum Toxin A injection into bladder or urethra. Urology 2005 65 : 37 41
18. Schulte-Baukloh H, Schobert J, Stolze T, Sturzebecher B, Weiss C, Knispel HH. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006 25 : 110 5
19. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006 49 : 528 35
20. Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005 96 : 848 52
21. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006 49 : 644 50
22. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor. an effective treatment idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005 24 : 231 6
23. Chapple C, Patel A. Botulinum toxin-new mechanisms, new therapeutic directions? Eur Urol 2006 49 : 606 8